• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Thermo Fisher Scientific Inc

    9/30/25 4:25:43 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials
    Get the next $TMO alert in real time by email
    FWP 1 ef20056493_fwp.htm FWP

    Issuer Free Writing Prospectus
    Filed Pursuant to Rule 433
    Registration No. 333-285159

    Thermo Fisher Scientific Inc.

    $500,000,000 4.200% Senior Notes due 2031 (the “2031 Notes”)
    $750,000,000 4.473% Senior Notes due 2032 (the “2032 Notes”)
    $750,000,000 4.794% Senior Notes due 2035 (the “2035 Notes”)
    $500,000,000 4.894% Senior Notes due 2037 (the “2037 Notes”)

    September 30, 2025

    Pricing Term Sheet

    Issuer:
    Thermo Fisher Scientific Inc.
    Securities:
    4.200% Senior Notes due 2031
    4.473% Senior Notes due 2032
    4.794% Senior Notes due 2035
    4.894% Senior Notes due 2037
       
    Aggregate Principal Amount:
    2031 Notes: $500,000,000
    2032 Notes: $750,000,000
    2035 Notes: $750,000,000
    2037 Notes: $500,000,000
       
    Stated Maturity Date:
    2031 Notes: March 1, 2031
    2032 Notes: October 7, 2032
    2035 Notes: October 7, 2035
    2037 Notes: October 7, 2037
       
    Issue Price:
    2031 Notes: 99.874% of the principal amount
    2032 Notes: 100.000% of the principal amount
    2035 Notes: 100.000% of the principal amount
    2037 Notes: 100.000% of the principal amount
       
    Coupon (Interest Rate):
    2031 Notes: 4.200% per annum
    2032 Notes: 4.473% per annum
    2035 Notes: 4.794% per annum
    2037 Notes: 4.894% per annum
       
    Yield to Maturity:
    2031 Notes: 4.227%
    2032 Notes: 4.473%
    2035 Notes: 4.794%
    2037 Notes: 4.894%
       
    Benchmark Treasury:
    2031 Notes: UST 3.625% due September 30, 2030
    2032 Notes: UST 3.875% due September 30, 2032
    2035 Notes: UST 4.250% due August 15, 2035
    2037 Notes: UST 4.250% due August 15, 2035
       
    Benchmark Treasury Price and Yield:
    2031 Notes: 99-17 ¼ / 3.727%
    2032 Notes: 99-22 ¾ / 3.923%
    2035 Notes: 100-27 / 4.144%
    2037 Notes: 100-27 / 4.144%
     

    Spread to Benchmark Treasury Yield:
    2031 Notes: 50 basis points
    2032 Notes: 55 basis points
    2035 Notes: 65 basis points
    2037 Notes: 75 basis points
       
    Interest Payment Dates:
    2031 Notes: March 1 and September 1 of each year, beginning on March 1, 2026
    2032 Notes: April 7 and October 7 of each year, beginning on April 7, 2026
    2035 Notes: April 7 and October 7 of each year, beginning on April 7, 2026
    2037 Notes: April 7 and October 7 of each year, beginning on April 7, 2026
       
    Make-Whole Call:
    2031 Notes: 10 basis points (prior to February 1, 2031)
    2032 Notes: 10 basis points (prior to August 7, 2032)
    2035 Notes: 10 basis points (prior to July 7, 2035)
    2037 Notes: 15 basis points (prior to July 7, 2037)
       
    Par Call:
    2031 Notes: On or after February 1, 2031
    2032 Notes: On or after August 7, 2032
    2035 Notes: On or after July 7, 2035
    2037 Notes: On or after July 7, 2037
       
    CUSIP / ISIN:
    2031 Notes: 883556DC3 / US883556DC34
    2032 Notes: 883556DD1 / US883556DD17
    2035 Notes: 883556DE9 / US883556DE99
    2037 Notes: 883556DF6 / US883556DF64
       
    Trade Date:
    September 30, 2025
       
    Settlement Date:
    October 7, 2025 (T+5); under Rule 15c6-1 under the Securities Exchange Act of 1934, trades in the secondary market generally are required to settle in one business day, unless the parties to that trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes before the first business day prior to the Settlement Date will be required, by virtue of the fact that the notes initially will settle on a delayed basis, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement and should consult their own advisors with respect to these matters.
     

    Trustee:
    The Bank of New York Mellon Trust Company, N.A.
       
    Joint Book-Running Managers:
    J.P. Morgan Securities LLC
    ING Financial Markets LLC
    Mizuho Securities USA LLC
    Scotia Capital (USA) Inc.
    Barclays Capital Inc.
    HSBC Securities (USA) Inc.
    Morgan Stanley & Co. LLC
       
    Co-Managers:
    BNP Paribas Securities Corp.
    BNY Mellon Capital Markets, LLC
    BofA Securities, Inc.
    Citigroup Global Markets Inc.
    Deutsche Bank Securities Inc.
    Drexel Hamilton, LLC
    Goldman Sachs & Co. LLC
    KeyBanc Capital Markets Inc.
    Loop Capital Markets LLC
    MUFG Securities Americas Inc.
    Nordea Bank Abp
    R. Seelaus & Co., LLC
    RBC Capital Markets, LLC
    SMBC Nikko Securities America, Inc.
    U.S. Bancorp Investments, Inc.
    UBS Securities LLC
    Wells Fargo Securities, LLC

    The offering is being made pursuant to an effective registration statement on Form S-3 (including a prospectus) filed with the U.S. Securities and Exchange Commission (the “SEC”). Before you invest, you should read the prospectus in that registration statement, the prospectus supplement related to the offering and the other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the joint book-running managers can arrange to send you the prospectus if you request it by calling J.P. Morgan Securities LLC collect at 1-212-834-4533, ING Financial Markets LLC toll-free at 1-877-446-4930, Mizuho Securities USA LLC toll-free at 1-866-271-7403 or Scotia Capital (USA) Inc. toll-free at 1-800-372-3930.



    Get the next $TMO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TMO

    DatePrice TargetRatingAnalyst
    9/11/2025$550.00Equal Weight → Overweight
    Barclays
    8/19/2025Outperform
    William Blair
    7/24/2025$510.00Buy → Hold
    HSBC Securities
    7/11/2025$590.00Sector Perform → Sector Outperform
    Scotiabank
    7/9/2025$460.00Buy → Neutral
    UBS
    1/10/2025$630.00Mkt Perform → Outperform
    Bernstein
    12/23/2024Sector Perform
    Scotiabank
    10/14/2024Buy
    Redburn Atlantic
    More analyst ratings

    $TMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes

    Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher") announced today that it has priced an offering of $2.5 billion aggregate principal amount (the "Offering") of the following notes: $500 million aggregate principal amount of its 4.200% senior notes due 2031 (the "2031 notes") at the issue price of 99.874% of their principal amount; $750 million aggregate principal amount of its 4.473% senior notes due 2032 (the "2032 notes") at the issue price of 100.000% of their principal amount; $750 million aggregate principal amount of its 4.794% senior notes due 2035 (the "2035 notes") at the issue price of 100.000% of their principal amount; and $500 million aggregate principal am

    9/30/25 8:00:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific Completes Acquisition of Sanofi's Ridgefield, New Jersey Site

    Expanded Strategic Partnership Enables Additional U.S. Manufacturing Capacity to Serve Increased Demand for Pharma/Biotech Customers Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced the completion of its acquisition of Sanofi's state-of-the-art sterile fill-finish and packaging site in Ridgefield, New Jersey, marking an expansion of the companies' strategic partnership to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. The Ridgefield facility is now part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment. Under the agreement, Thermo Fisher wil

    9/2/25 8:15:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific Completes Acquisition of Solventum's Purification and Filtration Business

    Highly Complementary Technologies Strengthen Thermo Fisher's Portfolio in Bioprocessing and Adjacent Markets Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher"), the world leader in serving science, today announced the completion of its acquisition of the Purification & Filtration business of Solventum (NYSE:SOLV) for approximately $4.0 billion in cash. With the transaction complete, the business, which is now Thermo Fisher's Filtration and Separation business, is part of the Life Sciences Solutions segment. The transaction includes Solventum's Purification & Filtration business serving Bioprocessing Filtration, Healthcare and Industrial Filtration, and Membranes1. The business s

    9/2/25 8:00:00 AM ET
    $SOLV
    $TMO
    Medical/Dental Instruments
    Health Care
    Industrial Machinery/Components
    Industrials

    $TMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chai Nelson sold $8,449 worth of shares (16 units at $528.09) and bought $11,038 worth of shares (20 units at $551.90), increasing direct ownership by 0.03% to 14,252 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    2/21/25 4:19:32 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Boxer Michael A bought $2,105 worth of shares (4 units at $526.15), increasing direct ownership by 0.03% to 13,101 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    10/6/23 4:23:51 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Thermo Fisher upgraded by Barclays with a new price target

    Barclays upgraded Thermo Fisher from Equal Weight to Overweight and set a new price target of $550.00

    9/11/25 8:36:39 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    William Blair initiated coverage on Thermo Fisher

    William Blair initiated coverage of Thermo Fisher with a rating of Outperform

    8/19/25 8:36:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Thermo Fisher from Buy to Hold and set a new price target of $510.00

    7/24/25 9:29:26 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Weisler Dion J

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    9/30/25 4:19:32 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Director Sperling Scott M

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    9/30/25 4:17:08 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Director Keith R. Alexandra

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    9/30/25 4:14:52 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    SEC Filings

    View All

    SEC Form FWP filed by Thermo Fisher Scientific Inc

    FWP - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    9/30/25 4:25:43 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form 424B5 filed by Thermo Fisher Scientific Inc

    424B5 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

    9/30/25 9:01:24 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

    9/2/25 8:03:06 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Financials

    Live finance-specific insights

    View All

    Thermo Fisher Scientific Reports Second Quarter 2025 Results

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 28, 2025. Second Quarter Highlights Second quarter revenue grew 3% to $10.85 billion. Second quarter GAAP diluted earnings per share (EPS) grew 6% to $4.28. Second quarter adjusted EPS was $5.36. Delivered excellent operational performance in the quarter, reflecting active management of our company in the macroenvironment demonstrating the strength of our proven growth strategy and the power of the PPI Business System. Advanced our proven growth strategy, launching a range of high-impact innovation, strengthening our industr

    7/23/25 6:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific Declares Quarterly Dividend

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on October 15, 2025, to shareholders of record as of September 15, 2025. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the

    7/10/25 4:15:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 23, 2025

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2025 before the market opens on Wednesday, July 23, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 523661. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under t

    7/1/25 8:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Thermo Fisher Scientific Inc (Amendment)

    SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    2/9/23 11:35:13 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed

    SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    2/10/21 11:57:23 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Leadership Updates

    Live Leadership Updates

    View All

    Thermo Fisher Scientific's Chief Financial Officer, Stephen Williamson, to Retire in Early 2026

    Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition

    7/23/25 9:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    908 Devices Appoints Christopher D. Brown to its Board of Directors

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

    6/16/25 8:00:00 AM ET
    $AAPL
    $MASS
    $RGEN
    Computer Manufacturing
    Technology
    Industrial Machinery/Components
    Industrials

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components